MIRA Pharmaceuticals, Inc.
MIRA
NASDAQ·Healthcare·Drug Manufacturers - General·Mkt cap $32.1M
$0.76
▲ +3.27%
P/E
—
Mkt Cap
$32.1M
52-Wk Range
$0.60–$2.45
52-Week Range
$0.60 - $2.45
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 44.6% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary synthetic THC analog technology with novel receptor targeting
- Focus on FDA-regulated pharmaceutical pathway for cannabinoid therapeutics
- Specialized expertise in CNS drug development for underserved neurological conditions
- Early-stage market positioning in therapeutic cannabinoid space before major competition
Bear Case
1 risk
- Above-average volatility (beta 1.5).
Growth
Stable outlook
Advancement of MIRA1a through clinical trial phases toward FDA approval
Value
Deep value opportunity - significant discount to sector peers
Momentum
Falling
-23.6% over 3m
Quality
Loss-making
Below average quality
Dividend
None
No dividend
Smart-money signal
Who's buying MIRA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Sep 2, 2026
AUG 12, 2026
Most recent quarter reported revenue of $0. Reported EPS of -$0.03.
Reported EPS · last 4Q
0 of 1 beats
Q3 26
—
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
Analyst coverage
Live ratings and price targets aggregated across covering analysts.
vs Industry
How MIRA stacks vs Drug Manufacturers - General
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.